THERAVECTYS

18 articles about THERAVECTYS

• NOVASEP and THERAVECTYS Enter Into a New License Agreement on DNA Flap Technology for GMP Manufacturing of Lentiviral Vectors

  4/18/2019

  Novasep, today announced the signing of a license agreement allowing Novasep to use Institut Pasteur's DNA Flap Technology to produce GMP-grade lentiviral vectors for clinical use in all therapeutic applications including gene therapy, cell therapy, immunotherapy and vaccination, for any customer, worldwide

• THERAVECTYS Taps Alain Clergeot as New CEO

  12/21/2015

• THERAVECTYS Appoints Dr. Jean-Pierre Bizzari To Board Of Directors

  9/25/2015

• THERAVECTYS To Present Detailed Phase I/II Results From The First-Ever Lentiviral-Vector Based Therapeutic Vaccine Trial At The 2015 Towards An HIV Cure Symposium

  7/20/2015

• THERAVECTYS Attends The American Society Of Gene & Cell Therapy & Presents A Progress Update On Its R&D And Production Activities

  5/13/2015

• THERAVECTYS Upped Hiring Almost Five-Fold in 2014, As Biotech Booms, Says HR Head

  5/1/2015

• THERAVECTYS Secures Exclusive Access To A Synthetic Humanized Nanobody Library From Institut Curie And Strengthens Its Proprietary Immunotherapeutic Platform

  4/14/2015

• THERAVECTYS to Hire Up to 25 As New French Manufacturing Plant Receives Approval

  3/27/2015

• THERAVECTYS Granted Authorization By The French National Agency For Medicines To Produce Lentiviral Vectors For Clinical Use And CAR-T Cell Therapies Under GMP Standards

  3/23/2015

• Delaware Court Finds That THERAVECTYS Is Reasonably Likely To Succeed On The Merits Of Its Tortious Interference Claim Against Immune Design Corporation

  3/11/2015

• THERAVECTYS Obtains Orphan Drug Designation From European Medicines Agency For Its Lentiviral Vector-Based Therapeutic Vaccine Against Adult T-Cell Leukemia And Lymphoma

  2/5/2015

• THERAVECTYS Secures €1.9 Million From Bpifrance

  1/26/2015

• THERAVECTYS Further Strengthens The Intellectual Property Of Its Lentiviral Vector Technology

  12/3/2014

• THERAVECTYS Provides Update On Its Phase 1/2 Lentiviral Vector-Based Therapeutic Vaccine Trial

  11/19/2014

• THERAVECTYS Files Suit In The U.S. Against Immune Design Corporation

  7/25/2014

• THERAVECTYS Finalizes The Recruitment Of Patients For The Phase I/II Clinical Trial Of Its Anti-HIV Therapeutic Vaccine Candidate

  2/5/2014

• THERAVECTYS Appoints A Head Of Clinical Development And A Head of Strategy And Business Development To Strengthen Its Executive Committee

  11/27/2013

• THERAVECTYS Raises $20 Million

  10/16/2013